BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...over the last five years and was CEO of Granngården AB from 2013 to 2015. CohBar Inc....
...strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum AB CohBar Inc. CorMedix...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...Huffnagle was president of the joint replacement division at Stryker Corp. (NYSE:SYK). Mitochondria-based therapeutics company CohBar Inc....
...took the reins in December following the departure of CEO Simon Allen, will remain on CohBar’s...
...& acquisitions worldwide at Johnson & Johnson (NYSE:JNJ) in 2010. BioCentury Staff Algiax Pharmaceuticals GmbH Aquestive Therapeutics Inc. CDx Diagnostics CohBar Inc. Engitix...
BioCentury | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

...general manager for three manufacturing facilities at Hitachi Chemical Advanced Therapeutics Solutions LLC (Allendale, N.J.). Cohbar Inc....
BioCentury | Mar 26, 2015
Distillery Therapeutics

Therapeutics: Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)

...young mice. Next steps include designing a long-acting version of the peptide. (See "Raising the CohBar"...
...open reading frame of the 12S rRNA-c (MOTS-c) LICENSING STATUS: Patent application filed; licensed to CohBar Inc....
BioCentury | Mar 26, 2015
Product R&D

Raising the CohBar

...DNA may deserve a second look as a source of therapeutic targets. A group from CohBar Inc....
...therapeutic targets might be encoded in mitochondrial DNA, although that has been the basis of CohBar's...
...has exclusively licensed all IP related to mitochondria-derived peptides to CohBar. Companies and Institutions Mentioned CohBar Inc....
BioCentury | Mar 11, 2013
Company News

CohBar Inc., Alzheimer's Drug Discovery Foundation neurology news

...CohBar received $205,260 in funding from ADDF to develop CohBar's Humanin analog, a mitochondrial peptide to...
...will support a year-long research program, including in vivo testing of the compound for AD. CohBar's...
...peptide, which inhibits cell death pathways that are active in AD and other neurological disorders. CohBar Inc....
Items per page:
1 - 6 of 6
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...over the last five years and was CEO of Granngården AB from 2013 to 2015. CohBar Inc....
...strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum AB CohBar Inc. CorMedix...
BioCentury | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

...Huffnagle was president of the joint replacement division at Stryker Corp. (NYSE:SYK). Mitochondria-based therapeutics company CohBar Inc....
...took the reins in December following the departure of CEO Simon Allen, will remain on CohBar’s...
...& acquisitions worldwide at Johnson & Johnson (NYSE:JNJ) in 2010. BioCentury Staff Algiax Pharmaceuticals GmbH Aquestive Therapeutics Inc. CDx Diagnostics CohBar Inc. Engitix...
BioCentury | Dec 12, 2018
Company News

Management tracks: Merck creates new commercial roles to follow Schechter's exit

...general manager for three manufacturing facilities at Hitachi Chemical Advanced Therapeutics Solutions LLC (Allendale, N.J.). Cohbar Inc....
BioCentury | Mar 26, 2015
Distillery Therapeutics

Therapeutics: Mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)

...young mice. Next steps include designing a long-acting version of the peptide. (See "Raising the CohBar"...
...open reading frame of the 12S rRNA-c (MOTS-c) LICENSING STATUS: Patent application filed; licensed to CohBar Inc....
BioCentury | Mar 26, 2015
Product R&D

Raising the CohBar

...DNA may deserve a second look as a source of therapeutic targets. A group from CohBar Inc....
...therapeutic targets might be encoded in mitochondrial DNA, although that has been the basis of CohBar's...
...has exclusively licensed all IP related to mitochondria-derived peptides to CohBar. Companies and Institutions Mentioned CohBar Inc....
BioCentury | Mar 11, 2013
Company News

CohBar Inc., Alzheimer's Drug Discovery Foundation neurology news

...CohBar received $205,260 in funding from ADDF to develop CohBar's Humanin analog, a mitochondrial peptide to...
...will support a year-long research program, including in vivo testing of the compound for AD. CohBar's...
...peptide, which inhibits cell death pathways that are active in AD and other neurological disorders. CohBar Inc....
Items per page:
1 - 6 of 6